Jim Cramer recently discussed Dynavax Technologies Corporation (NASDAQ: DVAX) on his program. A caller noted they had purchased the stock approximately three years ago at around $12 per share. Cramer responded directly to the caller.
"Congratulations. You know that one's done. They got that nice bid from Sanofi. I'm going to actually go out there and talk to them about that... Well played, my friend," Cramer said.
Sanofi (NASDAQ: SNY) announced on December 24 that it is acquiring Dynavax. The transaction is valued at nearly $2.2 billion. The offer involves a cash tender of $15.50 for each share of Dynavax.
Ryan Spencer, the Chief Executive Officer of Dynavax, provided a statement regarding the agreement. "We believe Sanofi's commercial reach, development capabilities and commitment to evidence-based immunization will amplify the opportunity for HEPLISAV-B and our innovative pipeline to address important public health needs, further advancing our mission to help protect the world against infectious disease," Spencer said. "We are confident that this transaction – and the compelling value it provides – is in the best interests of the Company and its stockholders."
Dynavax is a biopharmaceutical company. It develops and commercializes advanced vaccines, including a hepatitis B vaccine and an adjuvant used to enhance immune responses.